Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Therapy

Feasibility of NIH consensus criteria for chronic graft-versus-host disease

Leukemia volume 23, pages 78–84 (2009)Cite this article

Abstract

To assess the applicability of the National Institutes of Health (NIH) consensus criteria (NCC) for chronic graft-versus-host disease (cGVHD), 211 patients who developed GVHD more than 100 days after allogeneic transplantation were reclassified using NCC. Classifications were: late acute GVHD (44 patients, 21%), overlap syndrome (64 patients, 30%) and classic cGVHD (103 patients, 49%). Classic cGVHD and overlap syndrome patients (n=167) were graded using both the revised Seattle criteria (RSC) and NIH global scoring (NGS). Twenty-three patients (14%) had mild, 81 (48%) had moderate and 63 (38%) had severe cGVHD. After a median follow-up of 46 months (range 5–71 months), the 4-year GVHD-specific survival was not significantly different among the different subtypes of NCC. Among patients with late acute GVHD, however, the pattern of acute GVHD onset (late, persistent or recurrent) was significantly different with respect to GVHD-specific survival. Among patients with overlap syndrome and classic cGVHD, multivariate analysis showed that NGS as well as RSC were useful in predicting survival and discontinuation of immunosuppressive therapy despite of more detailed grouping. Our study indicates that NCC is applicable. The clinical impact of NIH types and NGS should be verified through prospective studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  2. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  3. Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.

    Article  CAS  PubMed  Google Scholar 

  4. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415–419.

    Article  CAS  PubMed  Google Scholar 

  5. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    Article  CAS  PubMed  Google Scholar 

  6. Min CK, Kim DW, Lee JW, Han CW, Min WS, Kim CC . Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica 2001; 86: 303–310.

    CAS  PubMed  Google Scholar 

  7. Kim HJ, Park CY, Park YH, Kim YJ, Kim DW, Min WS et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant 2003; 31: 79–86.

    Article  CAS  PubMed  Google Scholar 

  8. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449–3457.

    Article  CAS  PubMed  Google Scholar 

  9. Min CK, Kim SY, Lee MJ, Eom KS, Kim YJ, Kim HJ et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 149–156.

    Article  CAS  PubMed  Google Scholar 

  10. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  11. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 813–820.

    Article  PubMed  Google Scholar 

  12. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14–21.

    Article  CAS  PubMed  Google Scholar 

  13. Rocha V, Wagner Jr JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846–1854.

    Article  CAS  PubMed  Google Scholar 

  14. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  15. Remberger M, Aschan J, Lonnqvist B, Carlens S, Gustafsson B, Hentschke P et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol 2001; 66: 50–56.

    Article  CAS  PubMed  Google Scholar 

  16. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007; 13: 1207–1215.

    Article  PubMed  Google Scholar 

  17. Arora M, Nagaraj S, Witte J, DeFor TE, MacMillan ML, Burns LJ et al. New classification of chronic graft versus host disease: added clarity from the consensus diagnoses. Blood 2007; 110: 41.

    Google Scholar 

  18. Vogelsang GB . How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196–1201.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The statistical analyses performed in this article were advised by Catholic Medical Center Clinical Research Coordinating Center. We especially thank to Hyeon-Woo, Yim, MD, PhD and Seung-Hee, Jeong, MPH.

Author information

Authors and Affiliations

  1. Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, Korea

    B-S Cho, C-K Min, K-S Eom, Y-J Kim, H-J Kim, S Lee, S-G Cho, D-W Kim, J-W Lee, W-S Min & C-C Kim

Authors
  1. B-S Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C-K Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K-S Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S-G Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D-W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J-W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W-S Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C-C Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C-K Min.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cho, BS., Min, CK., Eom, KS. et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 23, 78–84 (2009). https://doi.org/10.1038/leu.2008.276

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.276

Keywords

This article is cited by

Search

Advanced search

Quick links